Table 2 |
||||||
|
28-Day all-cause mortality in patients with and those without heparin prophylaxis |
||||||
|
Any heparin |
No heparin |
|||||
|
|
|
|||||
|
INR ≥1.2 |
Placebo |
TFPI |
P |
Placebo |
TFPI |
P |
|
|
||||||
|
Positive blood culture |
||||||
|
n |
162 |
174 |
0.31 |
95 |
104 |
0.05 |
|
Mortality (%) |
32.7 |
28.2 |
40.0 |
26.9 |
||
|
Positive other |
||||||
|
n |
271 |
267 |
0.39 |
116 |
103 |
0.24 |
|
Mortality (%) |
30.6 |
34.5 |
45.7 |
37.9 |
||
|
Negative culture/not done |
||||||
|
n |
167 |
159 |
0.01 |
63 |
73 |
0.98 |
|
Mortality (%) |
25.7 |
39.6 |
41.3 |
41.1 |
||
|
|
||||||
|
Presented are 28-day all-cause mortality rates in patients with or without heparin prophylaxis during the study drug infusion period and with positive blood cultures, other documented infections, and negative culture or undocumented infections. INR, international normalized ratio; TFPI, Tissue factor pathway inhibitor. |
||||||
|
Laterre Critical Care 2008 12(Suppl 6):S4 doi:10.1186/cc7027 |
||||||